Pear Therapeutics Revenue and Competitors

Boston, MA USA



Total Funding

Estimated Revenue & Valuation

  • Pear Therapeutics's estimated annual revenue is currently $7.3M per year.(i)
  • Pear Therapeutics received $64.0M in venture funding in January 2019.
  • Pear Therapeutics's estimated revenue per employee is $121,800
  • Pear Therapeutics's total funding is $409M.

Employee Data

  • Pear Therapeutics has 60 Employees.(i)
  • Pear Therapeutics grew their employee count by -81% last year.

Pear Therapeutics's People

Head Health Economics and Real World EvidenceReveal Email/Phone
VP Regulatory AffairsReveal Email/Phone
VP, Government AffairsReveal Email/Phone
Head Enterprise Solutions & Professional ServicesReveal Email/Phone
Director, State Government AffairsReveal Email/Phone
Regional Business DirectorReveal Email/Phone
Executive Assistant to Chief Medical Officer & Head Clinical DevelopmentReveal Email/Phone
Sr. Director, IT & SecurityReveal Email/Phone
Associate Director, Payroll & Equity CompensationReveal Email/Phone
Case ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

What Is Pear Therapeutics?

At Pear, our mission is clear: we are pioneers in Prescription Digital Therapeutics, or PDTs. Our cross-functional team operates at the intersection of biotechnology and software technology. Pear discovers, develops, and delivers clinically-validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Every day, we push the boundaries of technology to transform medicine. Pear has a pipeline of products and product candidates across therapeutic areas, including mental health disorders, severe insomnia and multiple sclerosis. Our lead product, reSET®, treats Substance Use Disorder, and was the first PDT to receive marketing authorization from the FDA to treat disease. Pear's second product candidate, reSET-O for the treatment of Opioid Use Disorder, is currently under review by the FDA with Breakthrough Designation. For more information, visit us at

keywords:Biotechnology,Gaming,Healthcare,Human Resources Hr,Information Security,Medical Diagnostics,Mobile,Pharmaceuticals,Security


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Pear Therapeutics News

2022-04-17 - Pear Therapeutics to Present at 2022 Rx and Illicit Drug Summit

Pear to host panel discussion with leaders who are paving the way to provide patients access to prescription digital therapeutics for the...

2022-03-30 - Pear Therapeutics launches program to offer digital therapeutics ...

Boston-based Pear's program offers patients seeking treatment for substance use disorder (SUD) or opioid use disorder (OUD) access to a...

2022-03-22 - Pear Therapeutics ripens after SPAC pact, predicts quintupling of ...

In its first year-end financial report after going public via reverse merger last December, Pear Therapeutics inched past nearly all of its predictions for...

2021-06-22 - Pear Therapeutics Goes Public Via $1.6B SPAC Deal – Digital Health IPO

What You Should Know: – Pear Therapeutics, the leader in developing and commercializing prescription digital therapeutics to treat serious disease, and Thimble Point Acquisition Corp (Nasdaq: THMA), a special purpose acquisition company (SPAC) whose management team is associated with the Pritzk ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Pear Therapeutics Funding

DateAmountRoundLead InvestorsReference
2015-03-23$UndisclosedUndisclosed5AM VenturesArticle
2016-02-05$20.0MUndisclosed5AM VenturesArticle